Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07288177 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial sites expanded: 74 → 91 locationsEligibility criteria expanded, about 8 wordsShow 1 more changeShow less
Eligibility criteria expanded, about 8 words
MinorTrial sites expanded: 57 → 74 locationsv15
MinorTrial sites expanded: 41 → 57 locationsv14
MinorTrial sites expanded: 22 → 41 locationsv13
MinorTrial sites expanded: 15 → 22 locationsv12
MinorStudy sites: 13 to 15v11
MinorTrial sites expanded: 8 → 13 locationsv10
MinorTrial sites expanded: 2 → 8 locationsv9
Minor3 versionsRe-verified since Feb 3, 2026, no change to tracked fieldsv6-v8
MinorStart date changed from estimate of Feb 16, 2026 to Jan 30, 2026v5
MinorStudy sites: 1 to 2Start date: Jan 31, 2026 to Feb 16, 2026v4Show 1 more changeShow less
Start date: Jan 31, 2026 to Feb 16, 2026
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 1v3Show 1 more changeShow less
Study sites: 0 to 1
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 2 study will be conducted in different countries around the world with up to about 240 participants.
The purpose of this study is to evaluate how well Rina-S works against lung cancer.
The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo.
The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.
Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.